EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 5 (Mai 2025) Med Sci (Paris), 41 5 (2025) 416-424 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 5, Mai 2025
Enjeux et objectifs de la psychiatrie de précision
Page(s) 416 - 424
Section La psychiatrie de précision (PEPR PROPSY) : hypothèses et outils
DOI https://doi.org/10.1051/medsci/2025072
Published online 26 May 2025
  1. Perlman RL, Govindaraju DR, Garrod AE. The father of precision medicine. Genet Med 2016 ; 18 : 1088–9. [CrossRef] [PubMed] [Google Scholar]
  2. Giroux E, Gansel Y, Basbous L, et al. Oncologie et psychiatrie : pour une relation réciproque féconde. Med Sci (Paris) 2022 ; 38 : 381–6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Fernandes B, Williams L, Steiner J, et al. The new field of precision psychiatry. BMC Med 2017 ; 15 : 80. [CrossRef] [PubMed] [Google Scholar]
  4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001 ; 69 : 89–95. [CrossRef] [PubMed] [Google Scholar]
  5. Demazeux S, Pidoux V. Le projet RDoC : la classification psychiatrique de demain ? Med Sci (Paris) 2015 ; 31 : 792–6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Williams L, Carpenter W, Carretta C, et al. Precision psychiatry and research domain criteria: implications for clinical trials and future practice. CNS Spectr 2024 ; 29 : 26–39. [CrossRef] [PubMed] [Google Scholar]
  7. Cuthbert Bruce, Thomas Insel. Toward the future of psychiatric diagnosis: the seven pillars of RDoC ». BMC Med 2013 ; 11 : 126. [CrossRef] [PubMed] [Google Scholar]
  8. Sanislow Charles, Daniel Pine, Kevin Quinn, et al. Developing constructs for psychopathology research: research domain criteria ». J Abnorm Psychol 2010 ; 119 : 631–9. [CrossRef] [PubMed] [Google Scholar]
  9. Sensorimotor Domain Added to the RDoC Framework - National Institute of Mental Health (NIMH). 2019. https://www.nimh.nih.gov/news/science-news/2019/sensorimotor-domain-added-to-the-rdoc-framework [Google Scholar]
  10. Cuthbert B. Le cadre de travail des RDoC : faciliter la transition de la CIM et du DSM vers des approches dimensionnelles qui intègrent les neurosciences et la psychopathologie. Ann Med-Psychol 2021 ; 179 : 75–85. [Google Scholar]
  11. RDoC Matrix. National Institute of Mental Health (NIMH). s.d. Consulté le 27 décembre 2024. https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/constructs/rdoc-matrix [Google Scholar]
  12. Hakak-Zargar B, Tamrakar A, Voth T, et al. The utility of research domain criteria in diagnosis and management of dual disorders: a mini-review. Front Psychiatry 2022 ; 13 : 805163. [CrossRef] [PubMed] [Google Scholar]
  13. Leucht S, Hierl S, Kissling W, et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012 ; 200 : 97–106. [CrossRef] [PubMed] [Google Scholar]
  14. Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry 2022 ; 220 : 115–20. [CrossRef] [PubMed] [Google Scholar]
  15. McIntyre R, Alsuwaidan M, Bernhard T, et al. Treatment resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 2023 ; 22 : 394–412. [CrossRef] [PubMed] [Google Scholar]
  16. Lenze E, Nicol G, Barbour D, et al. Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders. J Psychiatry Neurosci 2021 ; 46 : E97–110. [CrossRef] [PubMed] [Google Scholar]
  17. Salazar de Pablo G, Studerus E, Vaquerizo-Serrano J, et al. Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice. Schizophr Bull 2021 ; 47 : 284–97. [CrossRef] [PubMed] [Google Scholar]
  18. Mcgorry P. Stage-specific treatment of psychotic disorders. Psychiatric Times 2020 ; 37 : 6. [Google Scholar]
  19. Di Lisi A, Pupo S, Menchetti M, et al. Antipsychotic treatment in people at clinical high risk for psychosis. J Clin Psychopharmacol 2024 ; 44 : 502–8. [CrossRef] [PubMed] [Google Scholar]
  20. Delaby C, Lehmann S. Vers un diagnostic biologique sanguin de la maladie d’Alzheimer ? Med Sci (Paris) 2024 ; 40 : 351–60. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  21. Leblond C, Rolland T, Barthome E, et al. A genetic bridge between medicine and neurodiversity for autism. Annu Rev Genet 2024 ; 58 : 487–512. [CrossRef] [PubMed] [Google Scholar]
  22. Gilgenkrantz H. La pléiotropie antagoniste et le paradoxe de la sénescence. Med Sci (Paris) 2025 ; 41 : 68. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  23. Chaumette B, Ferrafiat V, Ambalavanan A, et al. Missense variants in ATP1A3 and FXYD gene family are associated with childhood-onset schizophrenia. Mol Psychiatry 2020 ; 25 : 821–30. [CrossRef] [PubMed] [Google Scholar]
  24. Balestrini S, Mikati M, Álvarez-García-Rovés R, et al. Cardiac phenotype in ATP1A3-related syndromes: a multicenter cohort study. Neurology 2020 ; 95 : e2866–79. [CrossRef] [PubMed] [Google Scholar]
  25. Louveau C, Ellul P, Iftimovici A, et al. Neurodevelopmental disorders (NDD) without boundaries: research and interventions beyond classifications. J Neural Transm (Vienna) 2023 ; 130 : 473–9. [CrossRef] [PubMed] [Google Scholar]
  26. Tamminga CA, Pearlson G, Keshavan M, et al. Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. Schizophr Bull 2014 ; 40 : S131–7. [CrossRef] [PubMed] [Google Scholar]
  27. Dyar B, Meaddough E, Sarasua S, et al. Genetic findings as the potential basis of personalized pharmacotherapy in phelan-McDermid syndrome. Genes 2021 ; 12 : 1192. [CrossRef] [PubMed] [Google Scholar]
  28. Louveau C, Turtuluci MC, Consoli A, et al. Prader-Willi syndrome: symptoms and topiramate response in light of genetics. Front Neurosci 2023 ; 17 : 1126970. [CrossRef] [PubMed] [Google Scholar]
  29. Berry-Kravis E, Lindemann L, Jønch A, et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov 2018 ; 17 : 280–99. [CrossRef] [PubMed] [Google Scholar]
  30. Keary C, McDougle C. Current and emerging treatment options for Angelman syndrome. Expert Rev Neurother 2023 ; 23 : 835–44. [CrossRef] [PubMed] [Google Scholar]
  31. Pollak T, Lennox B, Müller S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 2020 ; 7 : 93–108. [CrossRef] [PubMed] [Google Scholar]
  32. Koutsouleris N, Buciuman MO, Vetter CS, et al. Distinct multimodal biological and functional profiles of symptom-based subgroups in recent-onset psychosis. Research Square 2024 ; mars, rs.3.rs-3949072 (preprint). [PubMed] [Google Scholar]
  33. Lema Y, Gamo N, Yang K, Ishizuka K. Trait and state biomarkers for psychiatric disorders: importance of infrastructure to bridge the gap between basic and clinical research and industry. Psychiatry Clin Neurosci 2018 ; 72 : 482–9. [CrossRef] [PubMed] [Google Scholar]
  34. Passos IC, Ballester B, Rabelo-da-Ponte FD, et al. Precision psychiatry: the future is now. Can J Psychiatry 2022 ; 67 : 21–5. [CrossRef] [PubMed] [Google Scholar]
  35. Parimbelli E, Sacchi M, Bellazzi R. Patient similarity for precision medicine: a systematic review. J Biomed Inform 2018 ; 83 : 87–96. [CrossRef] [PubMed] [Google Scholar]
  36. Koval I, Bône A, Louis M, et al. AD course map charts Alzheimer’s disease progression. Sci Rep 2021 ; 11 : 8020. [CrossRef] [PubMed] [Google Scholar]
  37. Marquand A, Rezek I, Buitelaar J, al. Understanding heterogeneity in clinical cohorts using normative models: beyond case-control studies. Biol Psychiatry 2016 ; 80 : 552–61. [CrossRef] [PubMed] [Google Scholar]
  38. Dumas M, Fay AF, Charpentier E, et al. Le jumeau numérique en santé : état des lieux et perspectives d’application à l’hôpital. Med Sci (Paris) 2023 ; 39 : 953–57. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  39. Spitzer M, Dattner I, Zilcha-Mano S. Digital twins and the future of precision mental health. Front Psychiatry 2023 ; 14 : 1082598. [CrossRef] [PubMed] [Google Scholar]
  40. Wickramasinghe N, Ulapane N, Sloane E, et al. Digital twins for more precise and personalized treatment. Stud Health Technol Inform 2024 ; 310 : 229–33. [PubMed] [Google Scholar]
  41. Verstuyft C, Dewolf D, Blin O, et al. How to facilitate the wider use of pharmacogenetic tests? Therapie 2024 ; décembre, S0040-5957(24)00215-4. [Google Scholar]
  42. Lewis C, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med 2020 ; 12 : 44. [CrossRef] [PubMed] [Google Scholar]
  43. PROPSY - Programme-Projet en Psychiatrie de Précision. s. d. Agence Nationale de la Recherche. Consulté le 27 décembre 2024. https://anr.fr/en/france-2030/programmes-et-equipements-prioritaires-de-recherchepepr/propsy-psychiatrie-de-precision/ [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.